C71T
CANCELLED SECTION 71
07/03/2026
Back to search
Official data from USPTO
MEDIGENE
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
36
Latest update
07/28/2026
Trademark type
Combined
Nice classes
5, 42, 44
Filing date
07/17/2018
Registration date
12/17/2019
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
07/03/2026
Last transaction
07/28/2026
Responsible office
United States Patent and Trademark Office
Status code
709
Official register
Principal Register
Drawing code
5
Owner type
27
Owner location
DE
Examiner
KIDWELL WALKER, JACLYN NOEMI
Law office
M40
Current location
TMO LAW OFFICE 113
Holders and representatives
Holders
Medigene Immunotherapies GmbH
Representatives
Lisa C. Pavento Meunier Carlin & Curfman LLC
Technical classification
Nice Classes
Class 5Class 42Class 44
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical and veterinary preparations namelycellular preparationsT-cell preparations and DC (dendritic cell) preparations for the treatment of cancer and use in immunotherapy; medical compositions for the treatment of hematological and solid tumorstumor precursors; test kits for diagnostic preparations for medical purposes for determining the type and existence of a tumor in a patient consisting primarily of antibodiestest kits for diagnostic preparations for medical purposes for determining the type and existence of a tumor in a patient consisting primarily of soluble T-cell receptorstest kits for diagnostic preparations for medical purposes for determining the type and existence of a tumor in a patient consisting primarily of genetically modified cells and test kits for diagnostic preparations for medical purposes for determining the type and existence of a tumor in a patient consisting of a composition of antibodiessoluble T-cell receptors and genetically modified cells; diagnostic and therapeutic preparations for medical purposes being mixtures of therapeutically active cells in a suitable mediumin particular produced using molecular biologicalbiotechnological and genetic methods
Class 42
Services in molecular biologyresearch and development in the field of medical and veterinary diagnosis and treatment using molecular biologicalbiotechnological and genetic methodsin the field of screening for compounds with pharmaceutical properties; development of test methods and test kits in the field of hematological and solid tumor immunology; biological cell analyses; development of individualized medicinedevelopment of treatment plans and therapy adapted for individual patients; all the foregoing being for scientific and therapeutic purposes; development of adoptive T cell therapy; development of DC vaccines; development of cellular tumour therapy; development of tumour markers; development of diagnostic and therapeutic antibodies; cell analyses; development of individualised medicinedevelopment of treatment plans and therapy adapted for individual patients
Class 44
Medical and veterinary medical servicesin particular extracting of blood and/or tissue samples and analysis and evaluation relating thereto for medical purposes
Publications
History of USPTO decisions and trademark events.
36 publications found
REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
12/17/2024
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
08/04/2022
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
08/04/2022
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
08/04/2022
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
08/04/2022
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
08/04/2022
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
05/01/2020
FICS
FINAL DISPOSITION NOTICE SENT TO IB
03/28/2020
FIMP
FINAL DISPOSITION PROCESSED
03/28/2020
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
03/17/2020
R.PR
REGISTERED-PRINCIPAL REGISTER
12/17/2019
GPNX
NOTIFICATION PROCESSED BY IB
10/05/2019
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
10/01/2019
PUBO
PUBLISHED FOR OPPOSITION
10/01/2019
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
09/18/2019
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
09/18/2019
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
09/11/2019
ALIE
ASSIGNED TO LIE
08/29/2019
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
08/22/2019
XAEC
EXAMINER'S AMENDMENT ENTERED
08/22/2019
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
08/22/2019
GNEA
EXAMINERS AMENDMENT E-MAILED
08/22/2019
CNEA
EXAMINERS AMENDMENT -WRITTEN
08/22/2019
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
08/13/2019
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
08/13/2019
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
08/13/2019
RFNT
REFUSAL PROCESSED BY IB
03/02/2019
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
02/14/2019
RFRR
REFUSAL PROCESSED BY MPU
02/14/2019
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
02/06/2019
CNRT
NON-FINAL ACTION WRITTEN
02/05/2019
MAFR
APPLICATION FILING RECEIPT MAILED
02/01/2019
DOCK
ASSIGNED TO EXAMINER
01/28/2019
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
01/28/2019
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
01/24/2019
Continuous trademark protection
Get notified about every new filing that threatens MEDIGENE or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.